List of Verquvo drug patents

Verquvo is owned by Merck Sharp Dohme.

Verquvo contains Vericiguat.

Verquvo has a total of 6 drug patents out of which 0 drug patents have expired.

Verquvo was authorised for market use on 19 January, 2021.

Verquvo is available in tablet;oral dosage forms.

Verquvo can be used as reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%.

Drug patent challenges can be filed against Verquvo from January, 2025.

The generics of Verquvo are possible to be released after 26 November, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10736896 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US8420656 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US9604948 MERCK SHARP DOHME Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Nov, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993476 MERCK SHARP DOHME Substituted 5-flouro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US8921377 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US11439642 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2026

Drugs and Companies using VERICIGUAT ingredient

NCE-1 date: January, 2025

Market Authorisation Date: 19 January, 2021

Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in